Synergy of daptomycin with fusidin against invasive systemic infection and septic arthritis induced by type IV group B streptococci in mice

摘要: In view of the emergence multidrug-resistant group B streptococci (GBS), and its significant clinical impact, there is a necessary need for development more effective therapeutic alternatives. Here, we assessed efficacy daptomycin, novel lipopeptide antibiotic, in treatment type IV GBS-induced invasive systemic infection septic arthritis mice. We also evaluated possible synergy between daptomycin fusidin to combat GBS disease. Mice infected with  GBS left without drug displayed high incidence deaths severe diffuse septic arthritis, associated excessive production proinflammatory cytokines (tumor necrosis factor alpha (TNF-α), interleukin-1beta (IL-1β) and interleukin-6 (IL-6)), cyclooxygeanse-2 (COX-2) prostaglandin E2 (PGE2) their blood joints. However, these GBS-infected mice significantly inhibited inoculated bacteria grow Daptomycin-treated had showed lower mortality rates, less frequent levels TNF-α, IL-1β, IL-6, COX-2 PGE2 than untreated animals. More interestingly, marked in vivo synergy that completely protected from serious sequels was clearly observed. summary, present study welcome newcomer antibacterial arsenal eradicate particular when given combination other agents such as fusidin.   Key words: Group streptococci, fusidin, cytokines, cylooxygenase-2, E2.